ThePigSite.com
5M Retail Now Open - Win a Ipad 2Sign up for ThePigSite weekly newsletterFollow us on Twitter
PMWS & PCVD


This free resource is kindly supported by: If you have a information you would like is to include in this section please contact us

Vaccination
Management
Disease Information
A PMWS update (Jake Waddilove)
ABOUT PMWS & PDNS
National Pork Board PMWS Fact Sheet
About PDNS (Jake Waddilive)
CEI Emerging Disease Notices: PMWS / PDNS
Conference and meetings archive
Case Histories
Yorkshire Farm, UK - Mike Muirhead - Final Update, June 2002
Mike Muirhead's case history of a Yorkshire farm with PMWS and PDNS.
East Anglia Farm, UK - Philip Richardson
This paper charts the course and effects of the disease on a single herd as well as highlighting the economic impact.
Photographs
Clinical signs
Photos of the clinical signs that are seen generally in pigs with PMWS and PDNS. Includes skin lesions, enlarged lymph glands, wasting and dead pigs.
Post mortem (1)
Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS. Includes interstitial pneumonia, secondary bacterial infection, enlarged lymph nodes, oedema and intra cytoplasmic inclusions
Post mortem (2)
More Photos of the signs that are seen in post-mortem samples of pigs with PMWS and PDNS.


PMWS Research Archives

Published Tuesday, February 01, 2011: Pig Journal Volume: 64
Experiences with Porcine Circovirus Type 2 (PCV2) Vaccination in North America and Europe
P. Maass, D. Strachan
Herd breakdowns with Porcine Circovirus Disease (PCVD) appeared to escalate to epizootic proportions in North America from 2004, following a similar pattern to that seen in Europe and the rest of the world since 1996. Fortunately, great advances had beenmade during this time in the understanding of the disease and the role of Porcine Circovirus type 2 (PCV2) which led to the development of different vaccine candidates against this devastating disease. The capsid protein encoded by the open reading frame two (ORF2) of PCV2 had been identified as the key immunogenic part of PCV2 inducing a protective immune response (Blanchard et al., 2003,Nawagitgul et al., 2000).

A one-shot PCV2 piglet vaccine using the ORF2 protein as antigen and an aqueous polymer in a buffered solution as adjuvant has been developed by Boehringer Ingelheim. Between its first introduction in North America in 2006 and August 2008, approximately 100million pigs have been successfully vaccinated with Ingelvac CircoFLEX®. The efficacy and safety has been documented in numerous field trials in different pig producing areas of the world. This paper reviews four North American trials and compares themto four European studies. In total,more than 30,000 pigs were included in these trials. Totalmortality was reduced by up to 75%in finishing barns,while PCVD relatedmortality was decreased in up to 89%in cases of severe Post-weaning Multisystemic Wasting Syndrome (PMWS). Cull pigs or runts were reduced at a similar level. Wherever reported, a significant increase in weight gain was achieved, even in subclinical situations. Differences in weight gain,where reported, ranged between + 2.4kg and + 6.8kg in favour of vaccinates. The average daily gain (ADG) in grow-finishing was improved in vaccinated groups by + 27 to + 32g/day in subclinical ormild forms of the diseases,whereas improvement reached + 44 to + 86g/day in clinical PMWS situations.

There were no reports of adverse reactions with the vaccine in these trials.Overall, both the closely controlled studies and themuch larger field experiences in Europe and North America confirmthe safety and, in particular, the excellent efficacy of this PCV2 vaccine in protecting piglets against themajor health and economic losses associated with PCVD when vaccinated fromtwo to three weeks of age onwards.


To continue reading this article please click here

Have you published information? To add please email the details

pcvd Merial BPEX PMWS, PCVD Technical Zone home page
 
Our Sponsors
Partners